Compositions and methods for inhibiting the activity of LAR family phosphatases

Patent metadata

Field	Value
Publication number	US-9937242-B2
Application number	US-201314391589-A
Country	US
Kind code	B2
Filing date	Apr 9, 2013
Priority date	Apr 9, 2012
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

A method of inhibiting and/or reducing the activity, signaling, and/or function of leukocyte-common antigen related (LAR) family of phosphatases in a cell of a subject induced by proteoglycans includes administering to the cell a therapeutic agent that inhibits one or more of catalytic activity, signaling, and function of the LAR family phosphatases without inhibiting binding to or activation the LAR family phosphatases by the proteoglycans.

First claim

Having described the invention, we claim:

1. A method of treating a neural injury in a subject in need thereof, the method comprising:
administering systemically to the subject a therapeutic agent that inhibits one or more of catalytic activity, signaling, and/or function of receptor protein tyrosine phosphatase sigma (PTPσ) without inhibiting binding to or activation of PTPσ by proteoglycans, wherein the therapeutic agent comprises a therapeutic peptide, the therapeutic peptide including the amino acid sequence of SEQ ID NO: 37.

2. The method of claim 1 , the neural injury comprising at least one of traumatic or toxic injuries to peripheral or cranial nerves, spinal cord or brain, traumatic brain injury, stroke, and cerebral aneurism.

3. The method of claim 1 , the therapeutic agent comprising a therapeutic peptide consisting of SEQ ID NO: 33.

4. The method of claim 1 , wherein the therapeutic agent includes a transport moiety that is linked to the therapeutic peptide and facilitates uptake of the therapeutic peptides by a cell.

5. The method of claim 4 , wherein the transport moiety is an HIV Tat transport moiety.

6. A pharmaceutical composition comprising:
a therapeutic agent that includes a synthetic therapeutic peptide and a transport moiety that is linked to the therapeutic peptide and facilitates uptake of the therapeutic peptide by a cell, the therapeutic peptide including the amino acid sequence of SEQ ID NO: 37.

7. The pharmaceutical composition of claim 6 , the therapeutic peptide including the amino acid sequence of SEQ ID NOs: 33.

8. The pharmaceutical composition of claim 6 , wherein the transport moiety is an HIV Tat transport moiety.

9. The pharmaceutical composition of claim 6 , wherein the therapeutic agent is a peptide having the amino acid sequence of SEQ ID NOs: 66.

10. The method of claim 1 , wherein the therapeutic agent is a peptide having the amino acid sequence of SEQ ID NO: 66.

Assignees

• Univ Case Western Reserve

Inventors

• Lang Bradley T
• Cregg Jared M
• Silver Jerry
• Weng Yi-Lan

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title